National Institute of Neurological Disorders and Stroke, Muscular Dystrophy Coordinating Committee Call for Committee Membership Nominations, 4674-4675 [2020-01319]
Download as PDF
<![CDATA[
4674
Federal Register / Vol. 85, No. 17 / Monday, January 27, 2020 / Notices
Place: The Ritz Carlton Hotel, 1700 Tysons
Boulevard, Conference Room: Old Dominion,
McLean, VA 22102.
Contact Person: Christine A. Livingston,
Ph.D., Scientific Review Officer, Office of
Scientific Review, National Center for
Advancing Translational Sciences (NCATS),
National Institutes of Health, 6701
Democracy Blvd., Democracy 1, Room 1073,
Bethesda, MD 20892, (301) 435–1348,
livingsc@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.859, Pharmacology,
Physiology, and Biological Chemistry
Research; 93.350, B—Cooperative
Agreements; 93.859, Biomedical Research
and Research Training, National Institutes of
Health, HHS)
Dated: January 21, 2020.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2020–01257 Filed 1–24–20; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Notice of
Closed Meetings
khammond on DSKJM1Z7X2PROD with NOTICES
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Cancer
Institute Special Emphasis Panel; NCI U01
Review: Integrating Biospecimen Science
Approaches into Clinical Assay.
Date: February 26, 2020.
Time: 12:00 p.m. to 2:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Cancer Institute Shady
Grove, 9609 Medical Center Drive, Room
7W244, Rockville, MD 20850 (Telephone
Conference Call).
Contact Person: John Paul Cairns, Ph.D.,
Scientific Review Officer, Research Programs
Review Branch, Division of Extramural
Activities, 9609 Medical Center Drive, Room
7W244, National Cancer Institute, NIH,
Bethesda, MD 20892, 240–276–5415,
paul.cairns@nih.gov.
Name of Committee: National Cancer
Institute Special Emphasis Panel; Improving
VerDate Sep<11>2014
16:54 Jan 24, 2020
Jkt 250001
Outcomes for Pediatric, Adolescent and
Young Adult Cancer Survivors (U01).
Date: March 17, 2020.
Time: 10:30 a.m. to 5:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Cancer Institute Shady
Grove, 9609 Medical Center Drive, Room
7W618, Rockville, MD 20850 (Telephone
Conference Call).
Contact Person: Mukesh Kumar, Ph.D.,
Scientific Review Officer, Research Program
Review Branch, Division of Extramural
Activities, 9609 Medical Center Drive, Room
7W618, National Cancer Institute, NIH,
Rockville, MD 20850 240–276–6611,
mukesh.kumar3@nih.gov.
Name of Committee: National Cancer
Institute Special Emphasis Panel; R13
Conference Grant Review.
Date: April 2, 2020.
Time: 10:30 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Cancer Institute Shady
Grove, 9609 Medical Center Drive, Room
7W554, Rockville, MD 20850 (Telephone
Conference Call).
Contact Person: Christopher L. Hatch,
Ph.D., Chief, Program Coordination &
Referral Branch, Division of Extramural
Activities, National Cancer Institute, NIH,
9609 Medical Center Drive, Room 7W554,
Rockville, MD 20850, 240–276–6454, ch29v@
nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.392, Cancer Construction;
93.393, Cancer Cause and Prevention
Research; 93.394, Cancer Detection and
Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology
Research; 93.397, Cancer Centers Support;
93.398, Cancer Research Manpower; 93.399,
Cancer Control, National Institutes of Health,
HHS)
Dated: January 21, 2020.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2020–01255 Filed 1–24–20; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Neurological
Disorders and Stroke, Muscular
Dystrophy Coordinating Committee
Call for Committee Membership
Nominations
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
The Office of the Secretary of
the Department of Health and Human
Services (HHS) is seeking nominations
for an individual to serve as a
nonfederal public member on the
SUMMARY:
PO 00000
Frm 00053
Fmt 4703
Sfmt 4703
Muscular Dystrophy Coordinating
Committee.
DATES: Nominations are due by 5:00
p.m. EDT on February 28, 2020.
ADDRESSES: Nominations must be sent
to Glen Nuckolls, Ph.D., by email to
nuckollg@ninds.nih.gov.
FOR FURTHER INFORMATION CONTACT: Glen
Nuckolls, Ph.D., by email to nuckollg@
ninds.nih.gov. or (301) 496–5745.
SUPPLEMENTARY INFORMATION: The
Muscular Dystrophy Coordinating
Committee (MDCC) is a federal advisory
committee established in accordance
with the Muscular Dystrophy
Community Assistance, Research, and
Education Amendments of 2001 (MD–
CARE Act; Pub. L. 107–84). The MD–
CARE Act was reauthorized in 2008 by
Public Law 110–361, and again in 2014
by Public Law 113–166. The MD–CARE
Act specifies that the committee
membership be composed of 2⁄3
governmental agency representatives
and 1⁄3 public members. We are seeking
nominations for four non-federal, public
members at this time, due to turnover of
committee membership. Nominations
will be accepted between January 28
and February 28, 2020.
Who is Eligible: Nominations are
encouraged for new or reappointment of
non-federal public members who can
provide the public and/or patient
perspectives to discussions of issues
considered by the Committee. Selfnominations and nominations of other
individuals are both permitted. Only
one nomination per individual is
required. Multiple nominations for the
same individual will not increase
likelihood of selection. Non-federal,
public members may be selected from
the pool of submitted nominations or
other sources as needed to meet
statutory requirements and to form a
balanced committee that represents the
diversity within the muscular dystrophy
communities. Nominations are
especially encouraged from leaders or
representatives of muscular dystrophy
research, advocacy, or service
organizations, individuals with
muscular dystrophy or their parents or
guardians. In accordance with White
House Office of Management and
Budget guidelines (FR Doc. 2014–
19140), federally-registered lobbyists are
not eligible.
Committee Composition: The
Department strives to ensure that the
membership of HHS Federal advisory
committees is fairly balanced in terms of
points of view represented and the
committee’s function. Every effort is
made to ensure that the views of all
genders, all ethnic and racial groups,
and people with disabilities are
E:\FR\FM\27JAN1.SGM
27JAN1
khammond on DSKJM1Z7X2PROD with NOTICES
Federal Register / Vol. 85, No. 17 / Monday, January 27, 2020 / Notices
represented on HHS Federal advisory
committees and, therefore, the
Department encourages nominations of
qualified candidates from these groups.
The Department also encourages
geographic diversity in the composition
of the Committee. Appointment to this
Committee shall be made without
discrimination on the basis of age, race,
ethnicity, gender, sexual orientation,
disability, and cultural, religious, or
socioeconomic status. Requests for
reasonable accommodation to enable
participation on the Committee should
be indicated in the nomination
submission.
Member Terms: Non-Federal public
members of the Committee serve for a
term of 3 years, and may serve for an
unlimited number of terms if
reappointed. Members may serve after
the expiration of their terms, until their
successors have taken office.
Meetings and Travel: As specified by
Public Law 113–166, the MDCC ‘‘shall
meet no fewer than two times per
calendar year.’’ Travel expenses are
provided for non-federal public
Committee members to facilitate
attendance at in-person meetings.
Members are expected to make every
effort to attend all full committee
meetings, twice per year, either in
person or via remote access.
Participation in relevant subcommittee,
working and planning group meetings,
and workshops, is also encouraged.
Submission Instructions and
Deadline: Nominations are due by 5
p.m. EDT on February 28, 2020, and
should be sent to Glen Nuckolls, Ph.D.,
by email to nuckollg@ninds.nih.gov.
Nominations must include contact
information for the nominee, a current
curriculum vitae or resume of the
nominee and a paragraph describing the
qualifications of the person to represent
some portion(s) of the muscular
dystrophy research, advocacy and/or
patient care communities.
More information about the MDCC is
available at https://mdcc.nih.gov/.
DEPARTMENT OF HOMELAND
SECURITY
Dated: January 16, 2020.
Walter J. Koroshetz,
Director, National Institute of Neurological
Disorders and Stroke, National Institutes of
Health.
Comments
[FR Doc. 2020–01319 Filed 1–24–20; 8:45 am]
BILLING CODE 4140–01–P
VerDate Sep<11>2014
16:54 Jan 24, 2020
Jkt 250001
U.S. Immigration and Customs
Enforcement
[OMB Control Number 1653–0048]
Agency Information Collection
Activities; Extension, Without Change,
of a Currently Approved Collection:
ICE Mutual Agreement Between
Government and Employers (IMAGE)
U.S. Immigration and Customs
Enforcement, Department of Homeland
Security.
ACTION: 60-Day notice.
AGENCY:
In accordance with the
Paperwork Reductions Act (PRA) of
1995 the Department of Homeland
Security (DHS), U.S. Immigration and
Customs Enforcement (ICE) will submit
the following Information Collection
Request (ICR) to the Office of
Management and Budget (OMB) for
review and clearance.
DATES: Comments are encouraged and
will be accepted until March 27, 2020.
ADDRESSES: All submissions received
must include the OMB Control Number
1653–0048 in the body of the letter, the
agency name and Docket ID ICEB–2020–
0001. All comments received will be
posted without change to https://
www.regulations.gov, including any
personal information provided. To
avoid duplicate submissions, please use
only one of the following methods to
submit comments:
(1) Online. Submit comments via the
Federal eRulemaking Portal website at
https://www.regulations.gov under eDocket ID number ICEB–2020–0001;
(2) Mail: Submit written comments to
DHS, ICE, Office of the Chief
Information Officer (OCIO), PRA
Clearance, Washington, DC 20536–5800.
FOR FURTHER INFORMATION CONTACT: For
specific question related to collection
activities, please contact: John Morris
(202–732–5409), john.j.morris@
ice.dhs.gov, U.S. Immigration and
Customs Enforcement.
SUPPLEMENTARY INFORMATION:
SUMMARY:
Written comments and suggestions
from the public and affected agencies
concerning the proposed collection of
information should address one or more
of the following four points:
(1) Evaluate whether the proposed
collection of information is necessary
for the proper performance of the
functions of the agency, including
whether the information will have
practical utility;
PO 00000
Frm 00054
Fmt 4703
Sfmt 4703
4675
(2) Evaluate the accuracy of the
agencies estimate of the burden of the
proposed collection of information,
including the validity of the
methodology and assumptions used;
(3) Enhance the quality, utility, and
clarity of the information to be
collected; and
(4) Minimize the burden of the
collection of information on those who
are to respond, including through the
use of appropriate automated,
electronic, mechanical, or other
technological collection techniques or
other forms of information technology,
e.g., permitting electronic submission of
responses.
Overview of This Information
Collection
(1) Type of Information Collection:
Extension, Without Change, of a
Currently Approved Collection.
(2) Title of the Form/Collection: U.S.
Immigration and Customs Enforcement
(ICE) Mutual Agreement between
Government and Employers (IMAGE)
Self-Assessment Questionnaire
(3) Agency form number, if any, and
the applicable component of the
Department of Homeland Security
sponsoring the collection: ICE Form 73–
028; U.S. Immigration and Customs
Enforcement.
(4) Affected public who will be asked
or required to respond, as well as a brief
abstract: Primary: Business or other forprofit; Not-for-profit institutions. The
U.S. Immigration and Customs
Enforcement Mutual Agreement
between Government and Employers
(IMAGE) program is the outreach and
education component of the Homeland
Security Investigations (HSI) Worksite
Enforcement (WSE) program. IMAGE is
designed to build cooperative
relationships with the private sector to
enhance compliance with immigration
laws and reduce the number of
unauthorized aliens within the
American workforce. Under this
program ICE will partner with
businesses representing a cross-section
of industries. A business will initially
complete and prepare an IMAGE
application so that ICE can properly
evaluate the company for inclusion in
the IMAGE program. The information
provided by the company plays a vital
role in determining its suitability for the
program. While 8 U.S.C. 1324(a) makes
it illegal to knowingly employ a person
who is not in the U.S. legally, there is
no requirement for any entity in the
private sector to participate in the
program and the information obtained
from the company should also be
available to the public.
E:\FR\FM\27JAN1.SGM
27JAN1
]]>Agencies
[Federal Register Volume 85, Number 17 (Monday, January 27, 2020)]
[Notices]
[Pages 4674-4675]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-01319]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute of Neurological Disorders and Stroke, Muscular
Dystrophy Coordinating Committee Call for Committee Membership
Nominations
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Office of the Secretary of the Department of Health and
Human Services (HHS) is seeking nominations for an individual to serve
as a nonfederal public member on the Muscular Dystrophy Coordinating
Committee.
DATES: Nominations are due by 5:00 p.m. EDT on February 28, 2020.
ADDRESSES: Nominations must be sent to Glen Nuckolls, Ph.D., by email
to [email protected].
FOR FURTHER INFORMATION CONTACT: Glen Nuckolls, Ph.D., by email to
[email protected]. or (301) 496-5745.
SUPPLEMENTARY INFORMATION: The Muscular Dystrophy Coordinating
Committee (MDCC) is a federal advisory committee established in
accordance with the Muscular Dystrophy Community Assistance, Research,
and Education Amendments of 2001 (MD-CARE Act; Pub. L. 107-84). The MD-
CARE Act was reauthorized in 2008 by Public Law 110-361, and again in
2014 by Public Law 113-166. The MD-CARE Act specifies that the
committee membership be composed of \2/3\ governmental agency
representatives and \1/3\ public members. We are seeking nominations
for four non-federal, public members at this time, due to turnover of
committee membership. Nominations will be accepted between January 28
and February 28, 2020.
Who is Eligible: Nominations are encouraged for new or
reappointment of non-federal public members who can provide the public
and/or patient perspectives to discussions of issues considered by the
Committee. Self-nominations and nominations of other individuals are
both permitted. Only one nomination per individual is required.
Multiple nominations for the same individual will not increase
likelihood of selection. Non-federal, public members may be selected
from the pool of submitted nominations or other sources as needed to
meet statutory requirements and to form a balanced committee that
represents the diversity within the muscular dystrophy communities.
Nominations are especially encouraged from leaders or representatives
of muscular dystrophy research, advocacy, or service organizations,
individuals with muscular dystrophy or their parents or guardians. In
accordance with White House Office of Management and Budget guidelines
(FR Doc. 2014-19140), federally-registered lobbyists are not eligible.
Committee Composition: The Department strives to ensure that the
membership of HHS Federal advisory committees is fairly balanced in
terms of points of view represented and the committee's function. Every
effort is made to ensure that the views of all genders, all ethnic and
racial groups, and people with disabilities are
[[Page 4675]]
represented on HHS Federal advisory committees and, therefore, the
Department encourages nominations of qualified candidates from these
groups. The Department also encourages geographic diversity in the
composition of the Committee. Appointment to this Committee shall be
made without discrimination on the basis of age, race, ethnicity,
gender, sexual orientation, disability, and cultural, religious, or
socioeconomic status. Requests for reasonable accommodation to enable
participation on the Committee should be indicated in the nomination
submission.
Member Terms: Non-Federal public members of the Committee serve for
a term of 3 years, and may serve for an unlimited number of terms if
reappointed. Members may serve after the expiration of their terms,
until their successors have taken office.
Meetings and Travel: As specified by Public Law 113-166, the MDCC
``shall meet no fewer than two times per calendar year.'' Travel
expenses are provided for non-federal public Committee members to
facilitate attendance at in-person meetings. Members are expected to
make every effort to attend all full committee meetings, twice per
year, either in person or via remote access. Participation in relevant
subcommittee, working and planning group meetings, and workshops, is
also encouraged.
Submission Instructions and Deadline: Nominations are due by 5 p.m.
EDT on February 28, 2020, and should be sent to Glen Nuckolls, Ph.D.,
by email to [email protected].
Nominations must include contact information for the nominee, a
current curriculum vitae or resume of the nominee and a paragraph
describing the qualifications of the person to represent some
portion(s) of the muscular dystrophy research, advocacy and/or patient
care communities.
More information about the MDCC is available at https://mdcc.nih.gov/.
Dated: January 16, 2020.
Walter J. Koroshetz,
Director, National Institute of Neurological Disorders and Stroke,
National Institutes of Health.
[FR Doc. 2020-01319 Filed 1-24-20; 8:45 am]
BILLING CODE 4140-01-P
